NEW YORK, July 19, 2018 /PRNewswire/ -- If you want a free Stock Review on ABIO, ACHV, ACOR, and ADAP sign up now at https://stocktraderreport.com/registration/. On Wednesday, July 18, 2018, US markets saw six out of nine sectors finishing the day in green, two in red, and one in neutral territory. Benchmark US indices were mixed at the end of yesterday's session - NASDAQ Composite was down 0.01%, closing at 7,854.44; the Dow Jones Industrial Average was 0.32% higher, finishing at 25,199.29; and the S&P 500 ended at 2,815.62, up 0.22%. Pre-market today, StockTraderReport.com scans the performance of the following four Biotechnology stocks: ARCA biopharma Inc. (NASDAQ: ABIO), Achieve Life Sciences Inc. (NASDAQ: ACHV), Acorda Therapeutics Inc. (NASDAQ: ACOR), and Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP). All you have to do is sign up today for this free limited time offer by clicking the link below.
On Wednesday, shares in USA-headquartered ARCA biopharma Inc. recorded a trading volume of 221,272 shares. The stock ended at $0.58, rising 0.11% from the last trading session. The Company's shares have gained 7.83% in the last month. The stock is trading above its 50-day moving average by 4.18%. Furthermore, shares of ARCA biopharma, which focuses on developing genetically-targeted therapies for cardiovascular diseases, have a Relative Strength Index (RSI) of 54.44. Get the full research report on ABIO for free by clicking below at:
Achieve Life Sciences
USA-based Achieve Life Sciences Inc.'s stock finished yesterday's session 0.89% lower at $3.33. A total volume of 170,641 shares was traded. The stock is trading below its 50-day moving average by 53.89%. Furthermore, shares of the Company, which develops and commercializes smoking cessation aids in the US and internationally, have an RSI of 30.70.
On July 11th, 2018, Achieve Life Sciences announced an update on the cytisine development program following a meeting conducted with the US FDA. Based on the FDA's recommendations to further characterize cytisine dosing prior to New Drug Application submission, the Company plans to conduct a Phase-2b optimization trial in approximately 250 smokers in the US, with various cytisine dosing schedules to evaluate overall treatment efficacy, safety, and compliance profiles for cytisine. ACHV's complimentary research coverage is a few simple steps away at:
At the close of trading on Wednesday, shares in USA-based Acorda Therapeutics Inc. saw a drop of 3.04%, ending the day at $28.70. The stock recorded a trading volume of 307,878 shares. The Company's shares have advanced 20.08% in the previous three months, 42.79% over the last twelve months, and 33.80% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 4.03% and 14.81%, respectively. Moreover, shares of Acorda Therapeutics, which identifies, develops, and commercializes therapies for neurological disorders in the US, have an RSI of 48.17. Register for your free research report on ACOR at:
United Kingdom-headquartered Adaptimmune Therapeutics PLC's shares ended the day 2.72% lower at $11.10 with a total trading volume of 433,690 shares, which was above their three months average of 393.97 thousand shares. The stock has gained 90.72% over the last twelve months and 66.17% on an YTD basis. The Company's shares are trading above their 200-day moving average by 13.77%. Additionally, shares of Adaptimmune Therapeutics, which focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor T-cell platform, have an RSI of 40.49. Stock Trader Report's downloadable research report on ADAP is available at:
Stock Trader Report:
Stock Trader Report (STR) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. STR has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
STR has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by STR. STR is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
STR, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. STR, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, STR, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither STR nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://stocktraderreport.com/privacy-policy/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 917-979-2038
Office Address: 22/F. 3 Lockhart Road, Wanchai Hong Kong
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/free-technical-briefing-on-biotech-stocks----arca-biopharma-achieve-life-sciences-acorda-therapeutics-and-adaptimmune-therapeutics-300683550.html
SOURCE Stock Trader Report